Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP II: Viprinex in Acute Ischemic Stroke
NCT00300196Phase 3Terminated
- Sponsor
- Neurobiological Technologies, Inc.
- Start
- Mar 2006
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 3 trial of ancrod in ischemic stroke, sponsored by Neurobiological Technologies, Inc.. Started Mar 2006; status: terminated.
02
Drugs
ancrod
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00300196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300196.